Trials: Palmoplantar Pustulosis (PPP)

Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Innovaderm Research Inc. Results Dec 2010 0.0% serious AE View details

N/A N=311 Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement

Persistent Postsurgical Pain

Primary: Number of Subjects With Post-Operative Persistent Pain (PPP) — 211; 34 Participants

Rush University Medical Center Results Dec 2019 0.0% serious AE View details

Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…

Amgen Results Apr 2025 3.1% serious AE View details

Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003

Amgen Results Jan 2022 1.7% serious AE View details

Phase 2 N=35 A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24

Aristea Therapeutics, Inc. Results Mar 2022 0.0% serious AE View details

Phase 2 N=59 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Primary: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) — -6.0; -6.1 score on a scale — p=0.944

Vanda Pharmaceuticals Results May 2022 1.7% serious AE View details

Phase 3 N=159 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001

Janssen Pharmaceutical K.K. Results Feb 2019 6.7% serious AE View details

Phase 2 N=152 A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Primary: The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline — -33.6; -44.2; -48.3; -46.2 Percentage of change in PPP ASI…

Boehringer Ingelheim Results Jul 2022 10.0% serious AE View details

Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Psoriasis

Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…

Boehringer Ingelheim Results Nov 2019 3.4% serious AE View details

Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)

Palmoplantar Pustulosis

Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001

Kristian Reich Results Sep 2021 0.0% serious AE View details

Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Psoriasis

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

AbbVie Results Jun 2024 2.9% serious AE View details

Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Palmoplantar Psoriasis

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Innovaderm Research Inc. Results Sep 2010 12.5% serious AE View details

N/A N=515 Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing

Elective Foot and Ankle Surgery.

Primary: Postoperative Infection and Delayed Wound Healing. — 2; 1; 17; 17 participants

Gary M. Kiebzak, Ph.D. Results May 2015 0.0% serious AE View details

Phase 3 N=23 Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

Psoriasis

Primary: Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions. — 4 participants

Merck Sharp & Dohme LLC Results Feb 2011 17.4% serious AE View details

Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Palmoplantar Pustular Psoriasis

Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722

Novartis Pharmaceuticals Results Jan 2019 12.5% serious AE View details

Clinical Trial Search

Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis

N/A N=311 Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement

Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

Phase 2 N=35 A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Phase 2 N=59 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Phase 3 N=159 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Phase 2 N=152 A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)

Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

N/A N=515 Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing

Phase 3 N=23 Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab